Curaleaf Holdings Property Deal Reels in Over $28 Million via Freehold Real Estate Group

  • Curaleaf Holdings will still be able to use the facilities that they sold, due to a sale-leaseback agreement.
  • Curaleaf previously received warnings from the FDA for advertising unproven benefits for CBD products.

The legalization efforts are progressing around the world, and Curaleaf Holdings Inc. wants to increase their chances of progress. Now, according to reports from Grizzle, the company has just netted over $28 million in a property deal with Freehold Properties. The terms of the sale-leaseback agreement allow Curaleaf to sell the ownership of several of their properties, while still being able to use the facilities.

With these sites that have already been placed under Freehold Properties’ ownership, Curaleaf will still be able to perform their grow operations, as well as processing, distributing, and dispensing products. On the new deal, CEO Joseph Lusardi of Curaleaf remarked that the agreement will give them “an additional stream of liquidity with an attractive cost of financing” that wasn’t available to the CBD industry before. With the proceeds, Lusardi explained that they’ll be expanding the company and increasing value for shareholders.

Curaleaf became the first major cannabis company in the US to get into trouble with the FDA over their health claims published on the hemp CBD products.

Since then, their goal has been to create more positive news around their company, and try to get ahead of the stock decline that occurred after their letter of warning, which happened just a week after a new compliance officer structure was implemented. The goal of the new structure was to ensure that the company is following the guidelines set out at the local, state, and federal levels, but it clearly didn’t happen in time for the FDA to be satisfied.

The FDA has gotten more involved with the CBD industry since the Farm Bill passed last year, leading CBD products to become more popular. Along with the warning letters that have been going out to multiple companies, the FDA has been working to release more regulations in the US, which are expected to be released by the end of 2019.

The Q2 2019 earnings report and conference call will happen at the close of businesses on August 27th, which is tomorrow. Other real estate deals will most likely be announced during the call or soon after, though the company already launched their Veterans Cannabis Project initiative this month.

Skylar Abbot

Skylar is a very valuable writer at COR with over a decade of decorated writing history as well as a Master’s Degree in Business. She considers herself an artist when it comes to authoring diverse guides and coherent reviews on many different topics of interest, especially the cannabis and CBD industries.

Share

Recent Posts

  • Gummies

Condor CBD Gummies – Shocking Customer Scam Concerns?

The Condor CBD Gummies have been the talk of the hemp-derived cannabidiol edibles as of…

2 years ago
  • Guides

Best Delta 8 THC Products – And Why You Need To Try Them

Delta 8 THC is a naturally occurring cannabinoid commonly produced from hemp-derived CBD. It’s relatively…

3 years ago
  • Guides

VidaCap: What To Know About the Best Mushroom Supplements Brand

With more people turning towards natural remedies in recent years, mushroom supplements have taken the…

3 years ago
  • Topicals & Salves

Circle Labs CBD: Legit Hemp Pain Relief Balm That Works?

The Circle Labs CBD Balm is extracted using a cold-infusion process and is an effective…

3 years ago
  • Gummies

Kara’s Orchards CBD Gummies: Safe Full Spectrum Hemp Extract

If anyone is looking for a CBD supplement that is packed with all the necessary…

3 years ago
  • Tinctures & Drops

Sage Elixir CBD: Legit Sage Elixir CBD Oil Tincture or Not?

If anyone has been searching the internet for all the benefits of CBD and where…

3 years ago